The incidence and mortality of global bladder cancer from 1990 to 2017_Chinese Journal of Evidence-Based Medicine

Authors：

HE Hairong ^1,2 , LI Li ³ , FENG Aozi ³ , GUO Xiaojuan ^2,4 ,  LV Jun ³

1. Clinical Research Center, the First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, P.R.China;
2. School of Public Health, Xi’An Jiaotong University, Xi’an 710061, P.R.China;
3. Department of Clinical Research, the First Affiliated Hospital of Jinan University, Guangzhou 510630, P.R.China;
4. Department of Neurology, the First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, P.R.China;

Corresponding author：

LV Jun, Email: lyujun2020@jnu.edu.cn

Keywords：

Bladder cancer; Incidence; Mortality; Age-period-cohort model; Joinpoint regression model

DOI：

10.7507/1672-2531.202007095

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objectives To analyze the trend of incidence and mortality of bladder cancer from 1990 to 2017 and the effects of age, time period and birth cohort on bladder cancer incidence and mortality.Methods Data on age-standardized incidence rate (ASIR) and age-standardized death rate (ASDR) of bladder cancer from 1990 to 2017 were extracted from the Global Burden of Disease 2017 (GBD 2017) database. Joinpoint regression model was used to analyze the average annual percentage change of ASIR and ASDR of bladder cancer. The age-period-cohort model was established to analyze the age, period and birth cohort effects on ASIR and ASDR of bladder cancer.Results From 1990 to 2017, both ASIR and ASDR of bladder cancer decreased slightly. ASIR decreased from 6.42 per 100 000 in 1990 to 6.04 per 100 000 in 2017, with an average annual percentage change of −0.9% (−1.0% to −0.8%), and ASDR decreased from 3.15 per 100 000 in 1990 to 2017 2.57/100 000, with an average annual percentage change of −0.4% (−0.4% to −0.3%). The age-period-cohort model results showed that as age increased, the risk of bladder cancer incidence and mortality increased; as the birth cohort progressed, the risk of bladder cancer morbidity and mortality decreased. The time period had little effect on the incidence and mortality of bladder cancer.Conclusions The incidence and mortality of bladder cancer are declining globally. On the other hand, the increase of the aging global population could reverse the incidence and mortality trend, active measures should be taken to address the adverse effects of aging.

Citation： HE Hairong, LI Li, FENG Aozi, GUO Xiaojuan, LV Jun. The incidence and mortality of global bladder cancer from 1990 to 2017. Chinese Journal of Evidence-Based Medicine, 2020, 20(11): 1257-1265. doi: 10.7507/1672-2531.202007095 Copy

1.	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6): 394-424.
2.	Cumberbatch K, He T, Thorogood Z, et al. Emerging drugs for urothelial (bladder) cancer. Expert Opin Emerg Drugs, 2017, 22(2): 149-164.
3.	Netto GJ, Tafe LJ. Emerging bladder cancer biomarkers and targets of therapy. Urol Clin North Am, 2016, 43(1): 63-76.
4.	Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med, 2003, 349(9): 859-866.
5.	Malats N, Real FX. Epidemiology of bladder cancer. Hematol Oncol Clin North Am, 2015, 29(2): 177-189.
6.	Fernández MI, Brausi M, Clark PE, et al. Epidemiology, prevention, screening, diagnosis, and evaluation: update of the ICUD-SIU joint consultation on bladder cancer. World J Urol, 2019, 37(1): 3-13.
7.	He H, Liu Q, Li N, et al. Trends in the incidence and DALYs of schizophrenia at the global, regional and national levels: results from the Global Burden of Disease Study 2017. Epidemiol Psychiatr Sci, 2020, 29: e91.
8.	Choi S, Chang J, Kim K, et al. Effect of smoking cessation and reduction on the risk of cancer in korean men: a population based study. Cancer Res Treat, 2018, 50(4): 1114-1120.
9.	Cumberbatch MG, Rota M, Catto JW, et al. The role of tobacco smoke in bladder and kidney carcinogenesis: a comparison of exposures and meta-analysis of incidence and mortality risks. Eur Urol, 2016, 70(3): 458-466.
10.	Ng M, Freeman MK, Fleming TD, et al. Smoking prevalence and cigarette consumption in 187 countries, 1980-2012. JAMA, 2014, 311(2): 183-192.
11.	Ebrahimi H, Amini E, Pishgar F, et al. Global, regional and national burden of bladder cancer, 1990 to 2016: results from the GBD study 2016. J Urol, 2019, 201(5): 893-901.
12.	Wipfli H, Samet JM. One hundred years in the making: the global tobacco epidemic. Annu Rev Public Health, 2016, 37: 149-166.
13.	Rosenberg AR, Kroon L, Chen L, et al. Insurance status and risk of cancer mortality among adolescents and young adults. Cancer, 2015, 121(8): 1279-1286.
14.	Niu X, Roche LM, Pawlish KS, et al. Cancer survival disparities by health insurance status. Cancer Med, 2013, 2(3): 403-411.
15.	DeRouen MC, Parsons HM, Kent EE, et al. Sociodemographic disparities in survival for adolescents and young adults with cancer differ by health insurance status. Cancer Causes Control, 2017, 28(8): 841-851.
16.	Ellis L, Canchola AJ, Spiegel D, et al. Trends in cancer survival by health insurance status in california from 1997 to 2014. JAMA Oncol, 2018, 4(3): 317-323.
17.	曹方政. 医疗保险制度的中日比较研究. 吉林: 吉林大学, 2017.
18.	屈水令, 邵晓颖, 刘学通, 等. 2005-2014年中国医院和专业公共卫生机构发展的比较研究. 中国公共卫生管理, 2017, 33(2): 259-262.
19.	Yang Y, Cheng Z, Jia X, et al. Mortality trends of bladder cancer in China from 1991 to 2015: an age-period-cohort analysis. Cancer Manag Res, 2019, 11: 3043-3051.
20.	Liu X, Jiang J, Yu C, et al. Secular trends in incidence and mortality of bladder cancer in China, 1990-2017: A joinpoint and age-period-cohort analysis. Cancer Epidemiol, 2019, 61: 95-103.
21.	Olfert SM, Felknor SA, Delclos GL. An updated review of the literature: risk factors for bladder cancer with focus on occupational exposures. South Med J, 2006, 99(11): 1256-1263.
22.	Cohen AK, Syme SL. Education: a missed opportunity for public health intervention. Am J Public Health, 2013, 103(6): 997-1001.

1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6): 394-424.
2. Cumberbatch K, He T, Thorogood Z, et al. Emerging drugs for urothelial (bladder) cancer. Expert Opin Emerg Drugs, 2017, 22(2): 149-164.
3. Netto GJ, Tafe LJ. Emerging bladder cancer biomarkers and targets of therapy. Urol Clin North Am, 2016, 43(1): 63-76.
4. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med, 2003, 349(9): 859-866.
5. Malats N, Real FX. Epidemiology of bladder cancer. Hematol Oncol Clin North Am, 2015, 29(2): 177-189.
6. Fernández MI, Brausi M, Clark PE, et al. Epidemiology, prevention, screening, diagnosis, and evaluation: update of the ICUD-SIU joint consultation on bladder cancer. World J Urol, 2019, 37(1): 3-13.
7. He H, Liu Q, Li N, et al. Trends in the incidence and DALYs of schizophrenia at the global, regional and national levels: results from the Global Burden of Disease Study 2017. Epidemiol Psychiatr Sci, 2020, 29: e91.
8. Choi S, Chang J, Kim K, et al. Effect of smoking cessation and reduction on the risk of cancer in korean men: a population based study. Cancer Res Treat, 2018, 50(4): 1114-1120.
9. Cumberbatch MG, Rota M, Catto JW, et al. The role of tobacco smoke in bladder and kidney carcinogenesis: a comparison of exposures and meta-analysis of incidence and mortality risks. Eur Urol, 2016, 70(3): 458-466.
10. Ng M, Freeman MK, Fleming TD, et al. Smoking prevalence and cigarette consumption in 187 countries, 1980-2012. JAMA, 2014, 311(2): 183-192.
11. Ebrahimi H, Amini E, Pishgar F, et al. Global, regional and national burden of bladder cancer, 1990 to 2016: results from the GBD study 2016. J Urol, 2019, 201(5): 893-901.
12. Wipfli H, Samet JM. One hundred years in the making: the global tobacco epidemic. Annu Rev Public Health, 2016, 37: 149-166.
13. Rosenberg AR, Kroon L, Chen L, et al. Insurance status and risk of cancer mortality among adolescents and young adults. Cancer, 2015, 121(8): 1279-1286.
14. Niu X, Roche LM, Pawlish KS, et al. Cancer survival disparities by health insurance status. Cancer Med, 2013, 2(3): 403-411.
15. DeRouen MC, Parsons HM, Kent EE, et al. Sociodemographic disparities in survival for adolescents and young adults with cancer differ by health insurance status. Cancer Causes Control, 2017, 28(8): 841-851.
16. Ellis L, Canchola AJ, Spiegel D, et al. Trends in cancer survival by health insurance status in california from 1997 to 2014. JAMA Oncol, 2018, 4(3): 317-323.
17. 曹方政. 医疗保险制度的中日比较研究. 吉林: 吉林大学, 2017.
18. 屈水令, 邵晓颖, 刘学通, 等. 2005-2014年中国医院和专业公共卫生机构发展的比较研究. 中国公共卫生管理, 2017, 33(2): 259-262.
19. Yang Y, Cheng Z, Jia X, et al. Mortality trends of bladder cancer in China from 1991 to 2015: an age-period-cohort analysis. Cancer Manag Res, 2019, 11: 3043-3051.
20. Liu X, Jiang J, Yu C, et al. Secular trends in incidence and mortality of bladder cancer in China, 1990-2017: A joinpoint and age-period-cohort analysis. Cancer Epidemiol, 2019, 61: 95-103.
21. Olfert SM, Felknor SA, Delclos GL. An updated review of the literature: risk factors for bladder cancer with focus on occupational exposures. South Med J, 2006, 99(11): 1256-1263.
22. Cohen AK, Syme SL. Education: a missed opportunity for public health intervention. Am J Public Health, 2013, 103(6): 997-1001.

Chinese Journal of Evidence-Based Medicine

The incidence and mortality of global bladder cancer from 1990 to 2017

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content